# Igor Puzanov

Source: https://onco.cc/people/igor-puzanov/  
OnCo record `igor-puzanov` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led the first talimogene laherparepvec plus ipilimumab study and co-wrote the immune toxicity management guidelines.

## Summary

Igor Puzanov is Director of the Early Phase Clinical Trials Program and Chief of the Melanoma Section at Roswell Park Comprehensive Cancer Center. He is a melanoma oncologist known for leading the first study of the oncolytic virus talimogene laherparepvec combined with ipilimumab, and for co-writing the guidelines on managing immune-related toxicity. His selected paper reports talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB to IV melanoma. He now directs Roswell Park's phase 1 programme and continues to work on oncolytic viruses.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Director, Early Phase Clinical Trials Program; Chief, Melanoma Section
- Specialisms: Melanoma; Oncolytic viruses; Immune-related toxicity

## Sources

- Roswell Park profile: https://www.roswellpark.org/igor-puzanov
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Puzanov%20I%5BAuthor%5D

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- technologies: [Oncolytic viruses](https://onco.cc/technologies/oncolytic-virus/)
- drugs: [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Talimogene laherparepvec](https://onco.cc/drugs/talimogene-laherparepvec/)
- institutions: [Roswell Park Comprehensive Cancer Center](https://onco.cc/institutions/roswell-park/)

---
JSON: https://onco.cc/api/v1/entities/igor-puzanov.json